Bevacizumab combination therapy: A review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer

BioDrugs

Volumn 27, Issue 4, 2013, Pages 375-392

  Dhillon, Sohita ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; GEMCITABINE; PACLITAXEL; PLATINUM DERIVATIVE; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

ABDOMINAL PAIN; ADVANCED CANCER; ARTERIAL THROMBOEMBOLISM; ARTICLE; ASTHENIA; BLEEDING; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY CANCER; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPERTENSION; INTESTINE PERFORATION; LEUKOPENIA; MAINTENANCE CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; OVARY CARCINOMA; PAIN; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SENSORY NEUROPATHY; SEPSIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; UTERINE TUBE CARCINOMA; VOMITING; WOUND HEALING IMPAIRMENT;

EID: 84880836347     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-013-0043-4     Document Type: Article

References (86)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Colombo N, Peiretti M, Parma G, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v23-30.
3. Vaughan S, Coward JI, Bast RC Jr, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11(10):719-25.
4. Burger RA. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol. 2007;25(20):2902-8.
5. Ledermann JA, Marth C, Carey MS, et al. Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer. Int J Gynecol Cancer. 2011;21(4):763-70.
6. Teoh DG, Secord AA. Antiangiogenic therapies in epithelial ovarian cancer. Cancer Control. 2011;18(1):31-43.
7. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358(19):2039-49.
8. Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 1999;85(1):178-87.
9. Brustmann H. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis. Gynecol Oncol. 2004;95(1):16-22.
10. Manenti L, Paganoni P, Floriani I, et al. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer. 2003;39(13):1948-56.
11. Wong C, Wellman TL, Lounsbury KM. VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer. Gynecol Oncol. 2003;91(3):513-7.
12. European Medicines Agency. Avastin: summary of product characteristics. 2013. http://www.emea.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/000582/WC500029271.pdf. Accessed 17 May 2013.
13. Lyseng-Williamson KA, Robinson DM. Bevacizumab: a review of its use in advanced colorectal cancer, breast cancer, and NSCLC. Am J Cancer. 2006;5(1):43-60.
14. Scott LJ. Bevacizumab: in first-line treatment of metastatic breast cancer. Drugs. 2007;67(12):1793-9.
15. Croom KF, Dhillon S. Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer. Drugs. 2011;71(16):2213-29.
16. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005;65(3):671-80.
17. Wang Y, Fei D, Vanderlaan M, et al. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7(4):335-45.
18. Mabuchi S, Terai Y, Morishige K, et al. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clin Cancer Res. 2008;14(23):7781-9.
19. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006;24(5):769-77.
20. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001;19(3):843-50.
21. Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol. 2001;19(3):851-6.
22. Hsei V, DeGuzman GG, Nixon A, et al. Complexation of VEGF with bevacizumab decreases VEGF clearance in rats. Pharm Res. 2002;19(11):1753-6.
23. Mabuchi S, Kawase C, Altomare DA, et al. Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary. Mol Cancer Ther. 2010;9(8):2411-22.
24. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57(20):4593-9.
25. Yanagisawa M, Yorozu K, Kurasawa M, et al. Bevacizumab improves the delivery and efficacy of paclitaxel. Anticancer Drugs. 2010;21(7):687-94.
26. Hu L, Hofmann J, Zaloudek C, et al. Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol. 2002;161(5):1917-24.
27. Oliva P, Decio A, Castiglioni V, et al. Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models. Br J Cancer. 2012;107(2):360-9.
28. Belotti D, Calcagno C, Garofalo A, et al. Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion. Mol Cancer Res. 2008;6(4):525-34.
29. Smerdel MP, Steffensen KD, Waldstrom M, et al. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Gynecol Oncol. 2010;118(2):167-71.
30. Han ES, Burger RA, Darcy KM, et al. Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. Gynecol Oncol. 2010;119(3):484-90.
31. Fuh K, Kiet T, Amanam I, et al. Immunoregulatory gene expression and response to bevacizumab in ovarian cancer: an analysis of the cancer genome atlas [abstract]. Gynecol Oncol. 2012;127(1):S15.
32. Alvarez-Secord A, Huh W, Tillmanns T, et al. Prognostic factors predictive of response to bevacizumab combined with chemotherapy in recurrent ovarian cancer: a multi-institutional study [abstract no. 234]. Gynecol Oncol. 2012;125 Suppl 1:S98-9.
33. Chase DM, Sill MW, Monk BJ, et al. Changes in tumor blood flow as measured by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II study. Gynecol Oncol. 2012;126(3):375-80.
34. Nick A, Stone R, Soliman P, et al. Pressure to respond: hypertension predicts clinical benefit from bevacizumab in recurrent ovarian cancer [abstract no. 84]. Gynecol Oncol. 2011;120 Suppl 1:S37.
35. Randall LM, Monk BJ. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol. 2010;117(3):497-504.
36. Stone RL, Sood AK, Coleman RL. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol. 2010;11(5):465-75.
37. Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother. 2009;43(3):490-501.
38. Wu JY, Wu XN, Ding L, et al. Phase I safety and pharmacokinetic study of bevacizumab in Chinese patients with advanced cancer. Chin Med J (Engl). 2010;123(7):901-6.
39. European Medicines Agency. Avastin: European public assessment report: scientific discussion. 2005. http://www.emea.europa.eu/docs/en-GB/document- library/EPAR-Scientific-Discussion/human/000582/WC500029262.pdf. Accessed 1 Feb 2013.
40. European Medicines Agency. Avastin: European public assessment report variation (H-C-582-II-41). 2011. http://www.emea.europa.eu/docs/en-GB/document- library/EPAR-Assessment-Report-Variation/human/000582/WC500120123.pdf. Accessed 21 Jan 2013.
41. European Medicines Agency. Avastin: European public assessment report (H-C-582-II-46). 2012. http://www.emea.europa.eu/docs/en-GB/document-library/ EPAR-Assessment-Report-Variation/human/000582/WC500135200.pdf. Accessed 22 Jan 2013.
42. Micha JP, Goldstein BH, Rettenmaier MA, et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer. 2007;17(4):771-6.
43. Penson RT, Dizon DS, Cannistra SA, et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010;28(1):154-9.
44. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473-83.
45. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer [erratum appears in N Engl J Med. 2012;366(3):284]. N Engl J Med. 2011;365(26):2484-96.
46. Monk BJ, Huang HQ, Burger RA, et al. Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2013;128(3):573-8.
47. Stark D, Nankivell M, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol. 2013;14(3):236-43.
48. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24(29):4699-707.
49. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer [erratum appears in J Clin Oncol. 2008;26(10):1773]. J Clin Oncol. 2007;25(33):5180-6.
50. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(33):5165-71.
51. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039-45.
52. Aghajanian C, Nycum LR, Goff B, et al. Updated overall survival analysis in OCEANS, a randomized phase 3 trial of gemcitabine (G) + carboplatin (C) and bevacizumab (Bv) or placebo (Pl) followed by Bv or Pl in platinum-sensitive recurrent epithelial ovarian (Roc), primary peritoneal (PPC) or fallopian tube cancer (FTC) [abstract no. 9670]. Ann Oncol. 2012;23(Suppl 9).
53. Burger R, Brady M, Bookman M, et al. Prospective investigation of risk factors for gastrointestinal adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer: a Gynecologic Oncology Group study [abstract no. 7]. Gynecol Oncol. 2011;120:S5.
54. Aghajanian C, Blank SV, Goff BA, et al. An updated safety analysis of OCEANS, a randomized, double-blind, phase III trial of gemcitabine (G) and carboplatin (C) with bevacizumab (BV) or placebo (PL) followed by BV or PL to disease progression (PD) in patients with platinum-sensitive (Plat-S) recurrent ovarian cancer [abstract no. 5054]. J Clin Oncol. 2012;30(15 Suppl).
55. Thigpen T. A rational approach to the management of recurrent or persistent ovarian carcinoma. Clin Obstet Gynecol. 2012;55(1):114-30.
56. Sato S, Itamochi H. Bevacizumab and ovarian cancer. Curr Opin Obstet Gynecol. 2012;24(1):8-13.
57. Bookman MA. The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer. Ann Oncol. 2010;21 Suppl 7:vii211-7.
58. Thigpen T, duBois A, McAlpine J, et al. First-line therapy in ovarian cancer trials. Int J Gynecol Cancer. 2011;21(4):756-62.
59. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup [erratum appears in J Clin Oncol. 2009;27(13):2305]. J Clin Oncol. 2009;27(9):1419-25.
60. Collinson FJ, Seligmann J, Perren TJ. Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents. Curr Oncol Rep. 2012;14(6):509-18.
61. Hall M, Gourley C, McNeish I, et al. Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer. 2013;108(2):250-8.
62. Heitz F, Harter P, Barinoff J, et al. Bevacizumab in the treatment of ovarian cancer. Adv Ther. 2012;29(9):723-35.
63. Chan J, Huh W, McClung C, et al. Factors predictive of toxicity associated with bevacizumab and chemotherapy in recurrent ovarian cancer: a multi-institutional study [abstract no. 163]. Gynecol Oncol. 2012;125 Suppl 1:S69.
64. Tanyi JL, McCann G, Hagemann AR, et al. Clinical predictors of bevacizumab-associated gastrointestinal perforation. Gynecol Oncol. 2011;120(3):464-9.
65. Richardson DL, Backes FJ, Hurt JD, et al. Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? Gynecol Oncol. 2010;118(1):47-51.
66. Diaz JP, Tew WP, Zivanovic O, et al. Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma. Gynecol Oncol. 2010;116(3):335-9.
67. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA. 2011;305(5):487-94.
68. Cohn D, Kim K, Resnick K, et al. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. Gynecol Oncol. 2010;1:S12-3.
69. Cooper K, Pickett K, Frampton G, et al. Bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of ovarian cancer: evidence review group report. On behalf of the National Institute of Health and Clinical Excellence 2012. http://www.nice.org.uk/nicemedia/live/13334/62103/ 62103.pdf. Accessed 30 Jan 2013.
70. Chan J, Monk B, Fuh K, et al. An economic analysis of bevacizumab in recurrent treatment of ovarian cancer [abstract no. 66]. Gynecol Oncol. 2011;120 Suppl 1:S29-30.
71. Walter A, Geisler J, Manahan K. Annual cost of bevacizumab in the adjuvant treatment of ovarian cancer to the U.S. Medicare system [abstract no. 263]. Gynecol Oncol. 2012;125 Suppl 1:S110-1.
72. Lesnock JL, Farris C, Krivak TC, et al. Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer. Gynecol Oncol. 2011;122(3):473-8.
73. London Cancer New Drugs Group. Rapid review: bevacizumab for the first-line treatment of advanced ovarian cancer in combination with paclitaxel and carboplatin. 2012. http://uat.medicinesresources.nhs.uk/en/NeLM-Area/ Evidence/Drug-Specific-Reviews/LCNDG-Rapid-Review-Bevacizumab-for-the-first- line-treatment-of-advanced-ovarian-cancer-in-combination-with-paclitaxel-and- carboplatin/. Accessed 30 Apr 2013.
74. Scottish Medicines Consortium. Bevacizumab: detailed advice. 2012. http://www.scottishmedicines.org.uk/files/advice/bevacizumab-Avastin.pdf. Accessed 3 May 2013.
75. Kroep JR, Nortier JWR. The role of bevacizumab in advanced epithelial ovarian cancer. Curr Pharm Des. 2012;18(25):3775-83.
76. Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol. 2010;11(12):1172-83.
77. Jayson GC, De Haas S, Delmar P, et al. Evaluation of plasma VEGFA as potential predictive pan-tumour biomarker for bevaizumab [abstract no. 804]. The European Multidisciplinary Cancer Congress; 23-27 Sep 2011; Stockholm.
78. Muggia F. Bevacizumab in ovarian cancer: unanswered questions. Drugs. 2012;72(7):931-6.
79. Raja FA, Chopra N, Ledermann JA. Optimal first-line treatment in ovarian cancer. Ann Oncol. 2012;23 Suppl 10:x118-27.
80. AGO Study Group. Evaluation of optimal initial treatment duration of bevacizumab in combination with standard chemotherapy in patients with ovarian cancer (BOOST) [ClinicalTrials.gov identifier NCT01462890]. US National Institutes of Health, ClinicalTrials.gov. 2012. http://www.clinicaltrials.gov/ ct2/show/NCT01462890?term=Bevacizumab+and+BOOST&rank=1. Accessed 24 Jan 2013.
81. European Society of Gynaecological Oncology. ENGOT-ov17/MITO 16: phase III trial with second line chemotherapy +/- bevacizumab in patients with platinum sensitive ovarian cancer recurrence after bevacizumab and chemotherapy in the first line. 2011. http://www.esgo.org/engot/Pages/ENGOTTrials.aspx. Accessed 25 Jan 2013.
82. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15(3):220-31.
83. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15(3):232-9.
84. Miles D, Harbeck N, Escudier B, et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol. 2011;29(1):83-8.
85. Pujade-Lauraine E, Hilpert F, Weber B, et al. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) [abstract no. LBA5002]. 48th Annual Meeting of the American Society of Clinical Oncology; 1-5 Jun 2012; Chicago (IL).
86. US National Institutes of Health. ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov. Accessed 25 Mar 2013.